Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price
on Aug 26, 2024
Agile Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 21.57 | 19.59 | 10.88 | 4.1 | 0.75 | - | Upgrade
|
| Revenue Growth (YoY) | 32.22% | 80.02% | 165.40% | 447.53% | - | - | Upgrade
|
| Cost of Revenue | 7.84 | 8.98 | 6.84 | 10.72 | 0.28 | - | Upgrade
|
| Gross Profit | 13.73 | 10.62 | 4.05 | -6.62 | 0.47 | - | Upgrade
|
| Selling, General & Admin | 25.49 | 28.27 | 42.23 | 58.14 | 36.02 | 9 | Upgrade
|
| Research & Development | 1.79 | 2.23 | 3.25 | 6.25 | 13.5 | 9.86 | Upgrade
|
| Operating Expenses | 27.28 | 30.5 | 45.48 | 64.39 | 49.52 | 18.86 | Upgrade
|
| Operating Income | -13.56 | -19.88 | -41.43 | -71.01 | -49.05 | -18.86 | Upgrade
|
| Interest Expense | -0.83 | -1.42 | -3.13 | -3.91 | -3.11 | - | Upgrade
|
| Interest & Investment Income | 0.08 | 0.08 | 0.08 | 0.03 | 0.31 | 0.25 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.55 | 6.76 | 25.52 | 3.83 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -15.86 | -14.47 | -18.97 | -71.07 | -51.85 | -18.61 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -11.12 | - | - | - | Upgrade
|
| Pretax Income | -15.86 | -14.47 | -30.09 | -71.07 | -51.85 | -18.61 | Upgrade
|
| Income Tax Expense | - | - | -4.68 | - | - | - | Upgrade
|
| Net Income | -15.86 | -14.47 | -25.41 | -71.07 | -51.85 | -18.61 | Upgrade
|
| Net Income to Common | -15.86 | -14.47 | -25.41 | -71.07 | -51.85 | -18.61 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 2 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 2 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 308.85% | 398.99% | 790.51% | 14.63% | 71.31% | 44.05% | Upgrade
|
| EPS (Basic) | -3.64 | -6.71 | -58.79 | -1464.21 | -1224.62 | -752.79 | Upgrade
|
| EPS (Diluted) | -3.64 | -6.71 | -58.79 | -1464.21 | -1224.62 | -752.79 | Upgrade
|
| Free Cash Flow | -1.71 | -9.58 | -36.08 | -65.47 | -47.66 | -15.79 | Upgrade
|
| Free Cash Flow Per Share | -0.39 | -4.44 | -83.48 | -1348.92 | -1125.69 | -638.74 | Upgrade
|
| Gross Margin | 63.63% | 54.18% | 37.19% | -161.35% | 62.35% | - | Upgrade
|
| Operating Margin | -62.85% | -101.49% | -380.69% | -1731.41% | -6549.13% | - | Upgrade
|
| Profit Margin | -73.52% | -73.83% | -233.48% | -1732.92% | -6922.96% | - | Upgrade
|
| Free Cash Flow Margin | -7.91% | -48.88% | -331.50% | -1596.46% | -6363.68% | - | Upgrade
|
| EBITDA | -13.15 | -19.5 | -39.9 | -68.78 | -48.78 | -18.7 | Upgrade
|
| EBITDA Margin | -60.99% | -99.52% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.4 | 0.39 | 1.53 | 2.22 | 0.28 | 0.16 | Upgrade
|
| EBIT | -13.56 | -19.88 | -41.43 | -71.01 | -49.05 | -18.86 | Upgrade
|
| EBIT Margin | -62.85% | -101.49% | - | - | - | - | Upgrade
|
| Advertising Expenses | - | - | 8.2 | 13.8 | 5.5 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.